ePrints

New and emerging treatments for metabolic dysfunction-associated steatohepatitis

Lookup NU author(s): Professor Quentin AnsteeORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2024 Elsevier Inc.Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide, with increasing incidence and prevalence in the setting of the obesity epidemic. MASH is also a leading indication for liver transplantation, given its associated risk of progression to end-stage liver disease. A key challenge in managing MASH is the lack of approved pharmacotherapy. In its absence, lifestyle interventions with a focus on healthy nutrition and regular physical activity have been the cornerstone of therapy. Real-world efficacy and sustainability of lifestyle interventions are low, however. Pharmacotherapy development for MASH is emerging with promising data from several agents with different mechanisms of action (MOAs) in phase 3 clinical trials. In this review, we highlight ongoing challenges and potential solutions in drug development for MASH and provide an overview of available data from emerging therapies across multiple MOAs.

Publication metadata

Author(s): Tincopa MA, Anstee QM, Loomba R

Publication type: Review

Publication status: Published

Journal: Cell Metabolism

Year: 2024

Volume: 36

Issue: 5

Pages: 912-926

Print publication date: 07/05/2024

Online publication date: 11/04/2024

Acceptance date: 02/04/2018

ISSN (print): 1550-4131

ISSN (electronic): 1932-7420

Publisher: Cell Press

URL: https://doi.org/10.1016/j.cmet.2024.03.011

DOI: 10.1016/j.cmet.2024.03.011

PubMed id: 38608696

Share